胰高糖素样肽-1激动剂联合钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病的影响

Effect of glucagon-like peptide 1 receptor agonist combined with sodium-glucose cotransporter 2 inhibitor on type 2 diabetes

近年来,全球糖尿病患病率逐年增加,其中2型糖尿病(type 2 diabetes mellitus,T2DM)占糖尿病总患病人数的90%~95%。胰高糖素样肽-1(glucagon-like peptide 1,GLP-1)激动剂联合钠-葡萄糖协同转运蛋白2抑制剂(sodium-glucose co-transporter 2 inhibitor,SGLT2)是治疗T2DM的新型降糖药物。本文讨论在给予规范的生活方式(饮食和运动)干预下,GLP-1激动剂联合SGLT2抑制剂对T2DM的安全性和有效性。

In recent years,the global prevalence of diabetes has increased year by year,and type II diabetes mellitus(T2DM)accounts for 90%–95%of the total diabetes cases.Glucagon-like peptide-1(GLP-1)agonist combined with sodium-glucose cotransporter 2(SGLT2)inhibitor is a new hypoglycemic drug for T2DM.This article will discuss the safety and efficacy of GLP-1 agonist combined with SGLT2 inhibitor in T2DM under the intervention of standard lifestyle(diet and exercise).